Prostate Cancer

An oncologic urologist from the United Kingdom (UK) discusses the diffusion of focal therapy options for clinically localized prostate cancer in the United States and UK.

Dr Mark Emberton reviews safety and efficacy data supporting the use of focal therapy in patients with prostate cancer.

An in-depth discussion of emerging focal therapy options for clinically localized prostate cancer.

Insights on the drawbacks of older treatment approaches for clinically localized prostate cancer and how strategically implementing focal therapies may address remaining unmet needs and clinical challenges.

Dr Emberton provides a historical perspective of treatment options for clinically localized prostate cancer and discussed how use of these options has evolved over time.

A prostate cancer specialist breaks down prostate cancer staging and grading and identifies several shortcomings of established risk stratification methods for patients with clinically localized disease.

Mark Emberton, BSc, MBBS, FRSC (Urol), MD, FMedSci describes his approach to diagnosing patients with prostate cancer, highlighting prostate-specific antigen (PSA) testing and magnetic resonance imaging (MRI) as critical to cancer detection.

The approval is based on findings from the phase 3 ARASENS trial.

The costimulatory bispecific antibody REGN5678 may alleviate resistance to immune checkpoint inhibition historically observed in prostate tumors.

Micro-ultrasound yielded comparable detection rates for prostate cancer as multiparametric magnetic resonance imaging.

“Coordination between urology and radiation oncology, if urology is placing the device, is really critical,” says Jonathan E. Shoag, MD.

The researchers combined machine learning and rule-based natural language processing to develop an algorithm that leveraged electronic health records to identify patients with nmCRPC.

A review of the currently available genomic testing options for patients with clinically localized prostate cancer and the NCCN and AUA/ASTRO recommendations based on risk group.

Stephen J. Freedland, MD, details which patient populations he orders genomic testing for, and how the tests can address clinical challenges in prostate cancer treatment.

The TAVT-45 formulation of abiraterone consists of granules for oral suspension and was created for patients with dysphagia who would have difficulty swallowing a tablet.

“Each patient is different, and some patients are more challenging than others in terms of placement,” says Jonathan E. Shoag, MD.

An expert urologist explains the potential for overtreatment of low-risk prostate cancer and undertreatment of high-risk prostate cancer and the potential consequences for patients.

A focused discussion on the challenges that urologists commonly face during the treatment decision-making process, and which factors typically inform treatment selection for clinically localized prostate cancer.

External beam radiotherapy plus or minus brachytherapy yielded lower rates of distant metastasis.

“It's really the overall excellence of a multidisciplinary program focused on improving patient outcomes,” says Daniel E. Spratt, MD.

"We feel a more appropriate approach would be to retain true Gleason 6 as a cancer of extremely low metastatic potential requiring close follow-up," write Harris et al.

In this interview, E. David Crawford, MD, discusses the development of luteinizing hormone-releasing hormone agonists and antagonists in prostate cancer.

“LHRH therapies are not going away. They are the standard of care,” says E. David Crawford, MD.

Dr Stephen Freedland outlines the currently available, NCCN-recommended treatment options for patients with high-risk, clinically localized prostate cancer, and the clinical challenges he faces during the treatment decision-making process.

Stephen J. Freedland, MD, describes the process of diagnosing, grading, staging, and stratifying risk for patients with prostate cancer and the typical tests he uses in his clinical practice.